GS GmbH Signs Technology License Agreement to Integrate Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) into Defibrillators and Pati
2009年8月20日 - 9:00PM
PRニュース・ワイアー (英語)
EMS Market Leader from Germany Standardizes on Masimo's
Revolutionary Rainbow SET Pulse CO-Oximetry Technology Platform
IRVINE, Calif. and KAUFERING, Germany, Aug. 20
/PRNewswire-FirstCall/ -- Masimo (NASDAQ:MASI), the inventor of
Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion
pulse oximetry, and GS Elektromedizinische Gerate G. Stemple GmbH,
a German developer and manufacturer of innovative medical equipment
for the Emergency Medical Services (EMS), today jointly announced a
worldwide technology licensing agreement to integrate Masimo
Rainbow SET Pulse CO-Oximetry into corpuls patient monitoring
modules. The agreement enables GS GmbH to expand the vital signs
and noninvasive measurement capabilities of its defibrillators and
patient monitoring systems to help EMS professionals detect and
treat life-threatening conditions earlier. The breakthrough
noninvasive blood constituent monitoring capabilities of Masimo
Rainbow SET Pulse CO-Oximetry allow for continuous monitoring of
hemoglobin, carbon monoxide, methemoglobin, PVI for fluid
responsiveness, perfusion index, and measure-through motion pulse
oximetry. With Masimo Rainbow SET, the ability to detect internal
bleeding, carbon monoxide poisoning, methemoglobinemia, fluid
responsiveness, perfusion, saturation, and pulse rate quickly,
easily and continuously can help save lives and improve patient
outcomes. According to Klaus Stemple, General Manager of GS GmbH,
the key to "developing better lifesaving support solutions and
techniques is to stay ahead of the mainstream. Our corpuls products
are innovative leaders in the defibrillator market and the
integration of Masimo Rainbow SET Pulse CO-Oximetry measurements is
another consistent step in the design and manufacture
state-of-the-art defibrillator/monitoring-systems that spearhead
the industry in patient monitoring performance. The combination of
corpuls and Masimo Rainbow SET creates a unique defibrillator
solution for EMS professionals looking to leverage additional vital
parameters to more thoroughly assess a patient's physiological
status and make better clinical and treatment decisions." The
corpuls3--a unique 3-in-1 modular defibrillator system combining
three components including: a compact patient box, a large
monitoring unit, and a defibrillator/pacer unit -- will be one of
the first products to feature Masimo Rainbow SET Pulse CO-Oximetry
capabilities. The Masimo Rainbow SET measurement option will be
available in mid-2010. Masimo Founder and CEO, Joe E. Kiani,
stated, "GS GmbH was one of the first European equipment
manufacturers to license Masimo SET pulse oximetry technology over
10 years ago. Today, they are still a market leader in providing
innovative EMS solutions throughout Europe and, with this
technology license agreement, will further expand the availability
of Masimo Rainbow SET Pulse CO-Oximetry to the benefit of patients
and EMS professionals alike." About GS GmbH GS Elektromedizinische
Gerate G. Stemple GmbH is a German company and
internationally-operated business specializing in the development
and manufacture of innovative high-end medical devices for
emergency medical services and intensive care for over 25 years.
The corpuls defibrillators and patient monitoring systems are
robust, reliable and durable devices designed for use in the first
aid treatment of people suffering from sudden cardiac arrest.
Additional information about corpuls and its products may be found
at http://www.corpuls.com/. About Masimo Masimo (NASDAQ:MASI)
develops innovative monitoring technologies that significantly
improve patient care--helping solve "unsolvable" problems. In 1995,
the company debuted Measure-Through Motion and Low-Perfusion pulse
oximetry, known as Masimo SET , which virtually eliminated false
alarms and increased pulse oximetry's ability to detect
life-threatening events. More than 100 independent and objective
studies demonstrate Masimo SET provides the most reliable SpO2 and
pulse rate measurements even under the most challenging clinical
conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse
CO-Oximetry(TM), a breakthrough noninvasive blood constituent
monitoring platform that can measure many blood constituents that
previously required invasive procedures. Masimo Rainbow SET
continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO ),
methemoglobin (SpMet ), and PVI(TM), in addition to oxyhemoglobin
(SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions.
Founded in 1989, Masimo has the mission of "Improving Patient
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring
to New Sites and Applications." Additional information about Masimo
and its products may be found at http://www.masimo.com/. Forward
Looking Statements This press release includes forward-looking
statements as defined in Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, in
connection with the Private Securities Litigation Reform Act of
1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the timing and commercial availability of corpuls3
featuring Masimo Rainbow SET Pulse CO-Oximetry technology, risks
related to our belief that Masimo Rainbow SET will provide
sufficient sensitivity and specificity to detect physiological
abnormalities in real-time, enabling EMS professionals to detect
and identify potentially life-threatening conditions earlier and
make better clinical and treatment decisions for their patients, as
well as other factors discussed in the "Risk Factors" section of
our most recent reports filed with the Securities and Exchange
Commission ("SEC"), which may be obtained for free at the SEC's
website at http://www.sec.gov/. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk
Factors" contained in our most recent reports filed with the SEC,
whether as a result of new information, future events or otherwise,
except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and
Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7,
Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse
CO-Oximeter are trademarks or registered trademarks of Masimo
Corporation. Corpuls and Corpuls3 are trademarks or registered
trademarks of GS Elektromedizinische Gerate G. Stemple GmbH. Media
Contacts: Dana Banks Masimo Corporation +1 (949) 297-7348
DATASOURCE: Masimo Corporation CONTACT: Dana Banks of Masimo
Corporation, +1-949-297-7348 Web Site: http://www.masimo.com/
http://www.corpuls.com/
Copyright